# New Overweight clinical trials: 1,105 posted since Nov 2024

Updated November 9, 2026.

1,105 clinical studies in overweight were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 384 have an industry sponsor and 622 are recruiting or about to. The newest, NCT07926152, was posted on November 9, 2026: Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes (German Diabetes Center).

## The full list

New Overweight clinical trials: 1,105 rows for $55.25, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 68 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/overweight

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 1,105
- Industry sponsored: 384
- Recruiting or not yet: 622
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 1,105, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926152 | Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes | German Diabetes Center | Not applicable | Not yet recruiting | Type 2 Diabetes (T2DM), Obesity & Overweight, Sarcopenia | 94 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926152) |
| November 9, 2026 | NCT07925684 | Determination of ED90 of Remimazolam Besylate Combined With Alfentanil for Gastroscopy Sedation in Obese Patients | Jianbo Wu | Not applicable | Recruiting | Procedural Sedation and Analgesia, Obesity & Overweight | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925684) |
| November 9, 2026 | NCT07924761 | A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living... | Kailera | Phase 1 | Not yet recruiting | Overweight or Obesity | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924761) |
| November 9, 2026 | NCT07924267 | A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic... | EktaH | Phase 1 | Completed | Obesity & Overweight, Overweight (BMI \> 30) | 120 | Tunisia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924267) |
| November 6, 2026 | NCT07923240 | Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional... | Research Center of Neurology, Russia | Phase 4 | Active not recruiting | Metabolic Abnormalities, Obesity & Overweight, Cerebral Atherosclerosis, Cerebrovascular Disease | 30 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923240) |
| November 6, 2026 | NCT07922798 | A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy... | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Not yet recruiting | Overweight , Obesity | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922798) |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | China, India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922330) |
| November 6, 2026 | NCT07922005 | Lifestyle Interventions and Genetic Scores for Weight Management | National and Kapodistrian University of Athens | Not applicable | Completed | Overweight , Obesity | 198 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922005) |
| November 6, 2026 | NCT07921940 | Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy | Medical University of Vienna | Not applicable | Active not recruiting | Obesity & Overweight, Gestational Diabetes Mellitus (GDM), Insulin Resistance, Maternal Obesity Complicating Pregnancy | 40 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921940) |
| November 6, 2026 | NCT07921316 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous... | Amgen | Phase 1 | Not yet recruiting | Obesity, Overweight | 356 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921316) |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919678) |
| November 5, 2026 | NCT07919158 | Impact of Dyslipidemia on Metabolic Health of Adults With Overweight/Obesity (IDOM): A Study at the San Raffaele Hospital Center for... | Rovere Querini Patrizia | Observational | Active not recruiting | Dyslipidemia, Obesity & Overweight | 900 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919158) |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918846) |
| November 5, 2026 | NCT07918625 | A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes | BrightGene Bio-Medical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obese Participants Without Diabetes | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918625) |
| November 4, 2026 | NCT07916194 | A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants | Beijing QL Biopharmaceutical Co.,Ltd | Phase 1 | Not yet recruiting | Overweight, Obesity | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916194) |
| November 4, 2026 | NCT07915609 | A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2 | 756 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915609) |
| November 4, 2026 | NCT07915245 | A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Eli Lilly and Company | Phase 1 | Not yet recruiting | Obesity, Overweight | 108 | Singapore, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915245) |
| November 3, 2026 | NCT07913685 | The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight... | Medical University of Bialystok | Phase 4 | Completed | Obesity & Overweight | 83 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913685) |
| November 2, 2026 | NCT07911514 | A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | AstraZeneca | Phase 1 | Not yet recruiting | Healthy Participants | 60 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911514) |
| November 2, 2026 | NCT07910916 | Effects of Concurrent Training on Serum PCSK9 Levels in Adults With Overweight | Kastamonu University | Not applicable | Recruiting | Overweight, Lipid Metabolism, Cholesterol Metabolism | 42 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910916) |
| November 2, 2026 | NCT07909772 | Effects of a Multispecies Probiotic on Metabolic, Liver, and Gut Health | University of Bari | Not applicable | Completed | Metabolic-Associated Steatotic Liver Disease, Diabetes (DM), Obesity & Overweight | 56 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909772) |
| November 2, 2026 | NCT07909109 | An Open Label Pilot Study Assessing the Impact of Chromium Picolinate Supplementation on Appetite and Cravings in Overweight Individuals | Nutrition 21, Inc. | Observational | Recruiting | Overweight (BMI > 25), Appetite, Craving | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909109) |
| November 2, 2026 | NCT07908823 | ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation | Affiliated Hospital to Academy of Military Medical Sciences | Not applicable | Not yet recruiting | Obesity & Overweight | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908823) |
| November 2, 2026 | NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After... | Amgen | Phase 1 | Recruiting | Obesity, Overweight | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908316) |
| October 30, 2026 | NCT07907029 | Transcutaneous Auricular Vagus Nerve Stimulation Combined With Lifestyle Intervention for Visceral Fat Reduction in Adults With Overweight... | Guangdong Provincial Hospital of Traditional Chinese Medicine | Not applicable | Not yet recruiting | Overweight, Obesity | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907029) |
| October 29, 2026 | NCT07902752 | Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs | George Washington University | Phase 2 | Not yet recruiting | Obesity & Overweight, Respiratory Depression, Intranasal Drug Administration, Oxytocin, Bariatric Surgery | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902752) |
| October 28, 2026 | NCT07901777 | Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity | Yuzuncu Yil University | Observational | Recruiting | Obesity & Overweight | 200 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901777) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 28, 2026 | NCT07900178 | Sustaining Health After an Intensive Weight-loss Pro-gramme | Copenhagen University Hospital, Hvidovre | Observational | Enrolling by invitation | Obesity & Overweight, Weight Loss, Weight Management in Adult Patients With Obesity or Overweight | 150 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900178) |
| October 27, 2026 | NCT07898267 | Gut Microbiota-Based Clinical Study of Akkermansia Supplementation for Overweight and Obesity | Second Affiliated Hospital of Nanchang University | Not applicable | Not yet recruiting | Obesity & Overweight | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898267) |
| October 27, 2026 | NCT07897890 | Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care | Indiana University | Not applicable | Completed | Obesity & Overweight, Breast Cancer | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897890) |
| October 27, 2026 | NCT07897682 | Impact of Significant Surgical Reduction of Adipose Tissue on Plasma Levels and Genetic Expression of Adipokines Associated With Ischemic... | King Edward Medical University | Not applicable | Not yet recruiting | Obesity & Overweight, Obesity Type I and II | 212 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897682) |
| October 27, 2026 | NCT07897383 | Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity | University Hospital, Gentofte, Copenhagen | Phase 1/2 | Not yet recruiting | Obesity & Overweight | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897383) |
| October 27, 2026 | NCT07897305 | Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients | Beijing Anzhen Hospital | Not applicable | Not yet recruiting | Atrial Fibrillation (AF), Ablation Treatment, Obesity & Overweight, Mazdutide | 700 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897305) |
| October 26, 2026 | NCT07896265 | Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes | Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | Overweight or Obesity Without Diabetes | 3,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896265) |
| October 26, 2026 | NCT07895563 | A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control | MNnutra | Not applicable | Active not recruiting | Overweight, Obesity, Weight Management, Appetite Control | 170 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895563) |
| October 26, 2026 | NCT07893743 | Changes in Intestinal Permeability and Systemic Inflammation Following Fast Food Overfeeding. | University Hospital, Gentofte, Copenhagen | Not applicable | Recruiting | Obesity & Overweight | 20 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893743) |
| October 26, 2026 | NCT07893717 | Motivational Interviewing Intervention for Families With Overweight and Obesity | Universidad Autonoma de Baja California | Not applicable | Active not recruiting | Obesity & Overweight | 120 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893717) |
| October 23, 2026 | NCT07893249 | Individual Variability in Energy Compensation After a 12-Week Supervised Exercise Intervention | Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences | Not applicable | Not yet recruiting | Physical Inactivity, Overweight, Obesity | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893249) |
| October 23, 2026 | NCT07891156 | Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2/3 | Recruiting | Type 1 Diabetes, Overweight , Obesity | 40 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891156) |
| October 22, 2026 | NCT07890870 | A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. | iBio, Inc. | Phase 1 | Not yet recruiting | Obesity & Overweight | 32 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890870) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | Argentina, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 22, 2026 | NCT07889570 | A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression | Evolv | Not applicable | Completed | Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression, Weight Management | 98 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889570) |
| October 21, 2026 | NCT07886788 | Study of Grape Consumption in Adaptation to Seasonal Photoperiod | University Rovira i Virgili | Not applicable | Active not recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight, Obesity & Overweight | 46 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886788) |
| October 21, 2026 | NCT07884903 | Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks | Shanxi Bethune Hospital | Observational | Not yet recruiting | Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)... | 25,974 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884903) |
| October 20, 2026 | NCT07884058 | IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity | University of Yaounde 1 | Phase 2 | Not yet recruiting | Obesity & Overweight | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884058) |
| October 20, 2026 | NCT07883031 | Effects of Yerba Mate Supplementation on Metabolic Health, Physical Function, and Cognition in Older Adults With Excess Adiposity | University of North Alabama | Not applicable | Completed | Overweight (BMI \> 25), Obesity & Overweight | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883031) |
| October 20, 2026 | NCT07882654 | A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN... | EktaH | Phase 2 | Not yet recruiting | Obesity / Overweight, Obesity (BMI Equal to or \>30) | 31 | Tunisia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882654) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Not yet recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | Singapore, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 19, 2026 | NCT07881770 | Semaglutide Health Outcomes and Patient Adherence in Australia | Novo Nordisk A/S | Observational | Not yet recruiting | Overweight, Obesity | 10,000 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881770) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | Brazil, China, Germany, Japan, Puerto Rico, Romania, South Korea, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07880717 | Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years | Mahidol University | Observational | Recruiting | Diabete Mellitus, Dyslipidaemia, Chronic Kidney Disease, Psychiatric Disorder, Hypertension, Hypothyroidism, Smoking... | 93 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880717) |
| October 15, 2026 | NCT07877038 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Not yet recruiting | Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | 32 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877038) |
| October 15, 2026 | NCT07876531 | A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or... | Pfizer | Phase 1 | Recruiting | Overweight and/or Obesity, Healthy Participants | 144 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876531) |
| October 15, 2026 | NCT07876518 | A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity | Pfizer | Phase 1 | Not yet recruiting | Overweight and/or Obesity | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876518) |
| October 15, 2026 | NCT07874828 | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Sarcoma,Soft Tissue | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874828) |
| October 15, 2026 | NCT07874633 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight | 432 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874633) |
| October 14, 2026 | NCT07873762 | Effects of a 12-Week Individualized Energy-Restricted Diet on Perceived Stress and Serum Cortisol in Adults With Overweight or Obesity | Acibadem University | Not applicable | Completed | Obesity & Overweight | 30 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873762) |
| October 14, 2026 | NCT07873645 | Study of UBT37034 Injection | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Recruiting | Overweight , Obesity | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873645) |
| October 14, 2026 | NCT07872904 | FutureShape Family | Signe Torekov | Phase 4 | Recruiting | Obesity, Overweight | 400 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872904) |
| October 13, 2026 | NCT07871565 | Time-Restricted Eating With or Without Energy Restriction in Dyslipidemic Women With Owerweight or Obesity | Acibadem University | Not applicable | Completed | Dyslipidemia, Obesity & Overweight | 56 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871565) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 13, 2026 | NCT07870668 | Intermittent Phentermine for Obesity and Body Composition | OSCAR MANUEL TORRES FALCON | Phase 4 | Completed | Obesity & Overweight | 600 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870668) |
| October 13, 2026 | NCT07870538 | A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge... | Universitaire Ziekenhuizen KU Leuven | Phase 4 | Recruiting | Obesity & Overweight | 96 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870538) |
| October 13, 2026 | NCT07869758 | Gastric On in Obesity Management: Evaluation of the Safety and Efficacy of the 6-Month Gastric Balloon (Prospective) | Rigicon, Inc. | Not applicable | Completed | Obesity & Overweight | 42 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869758) |
| October 9, 2026 | NCT07868354 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868354) |
| October 8, 2026 | NCT07866066 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Amgen | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 1,300 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866066) |
| October 6, 2026 | NCT07861529 | Effects of Posterior Gastropexy During Sleeve Gastrectomy on Quality of Life | Helwan University | Not applicable | Completed | Obesity & Overweight | 50 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861529) |
| October 6, 2026 | NCT07861048 | Active Versus Passive Recovery During HIIT in Children With Overweight or Obesity | High Institute of Sports and Physical Education of Kef | Not applicable | Completed | Overweight and Obesity | 30 | Tunisia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861048) |
| October 5, 2026 | NCT07859072 | WB-EMS Combined With Nutritional Guidance for a High-Protein Diet on Body Composition, Muscle Function, Psychological and Functional... | Universidade Cesumar (UNICESUMAR) | Not applicable | Not yet recruiting | Overweight (BMI > 25), Obesity & Overweight, Aging | 36 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859072) |
| October 5, 2026 | NCT07857473 | A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants | Immunwork, Inc. | Phase 2 | Not yet recruiting | Overweight and Obesity | 204 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857473) |
| October 5, 2026 | NCT07857018 | Long-term Follow-up After Childhood Obesity | Ulla Toft | Observational | Not yet recruiting | Overweight , Obesity | 6,100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857018) |
| October 5, 2026 | NCT07856784 | Cognitive and Behavioral Approaches to Reduce Binge Eating and Excess Weight in Adolescents (Online) | Indiana University | Not applicable | Not yet recruiting | Binge Eating, Overweight and Obesity, Eating Disorders in Adolescence | 159 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856784) |
| October 2, 2026 | NCT07855939 | Long-term Iron Absorption and Loss in Women | Mahidol University | Observational | Recruiting | Obesity & Overweight, Normal Weight Adults | 64 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855939) |
| October 2, 2026 | NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855133) |
| October 2, 2026 | NCT07853898 | Effects of Pistachios on Postprandial Metabolic Responses in Adults With Overweight or Obesity | St. Louis University | Not applicable | Recruiting | Obesity / Overweight | 28 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853898) |
| October 1, 2026 | NCT07850960 | Effect of Omeprazole on Gut Microbiota in Adults With Obesity and GERD | Federal State Budgetary Scientific Institution | Phase 4 | Not yet recruiting | Obesity & Overweight, Gastroesophageal Reflux Disease | 26 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850960) |
| September 30, 2026 | NCT07850765 | Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets | Novo Nordisk A/S | Observational | Completed | Overweight, Obesity | 1,260 | Israel, Mexico, Saudi Arabia, South Africa, Turkey (Türkiye), United Arab... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850765) |
| September 30, 2026 | NCT07850531 | Precision Nutrition for Obesity and Prediabetes Prevention in Under-supported Communities | Prairie View A&M University | Not applicable | Not yet recruiting | Obesity & Overweight, Prediabetes | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850531) |
| September 30, 2026 | NCT07850466 | TRPTI Metabolic and GLP-1 Pharmacodynamic Study | RDC Clinical Pty Ltd | Phase 4 | Not yet recruiting | Overweight , Obesity | 20 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850466) |
| September 30, 2026 | NCT07849439 | Two-Week Stair-Climbing Exercise Snacks and Metabolic Health in Adults With Overweight or Obesity: A Pilot Study | St. Louis University | Not applicable | Recruiting | Overweight , Obesity | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849439) |
| September 29, 2026 | NCT07847515 | Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients | Nanjing First Hospital, Nanjing Medical University | Observational | Not yet recruiting | Obesity / Overweight | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847515) |
| September 29, 2026 | NCT07847307 | ENDOBARIHEART STUDY | Maria Cecilia Hospital | Not applicable | Not yet recruiting | Obesity & Overweight | 50 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847307) |
| September 29, 2026 | NCT07846865 | Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea | Woolcock Institute of Medical Research | Phase 2/3 | Not yet recruiting | Sleep Apnoea, Obesity & Overweight, Sleep Apnea Syndrome, Obstructive | 256 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846865) |
| September 29, 2026 | NCT07845773 | Effects of Antenatal Nutrition Counseling on Maternal and Infant Outcomes | Eastern Mediterranean University | Not applicable | Completed | Overweight, Pregnancy | 108 | Cyprus | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845773) |
| September 29, 2026 | NCT07845578 | A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Obesity, Overweight | 60 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845578) |
| September 29, 2026 | NCT07845513 | A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | Pfizer | Phase 1 | Active not recruiting | Overweight, Obesity, Healthy Adults | 11 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845513) |
| September 29, 2026 | NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity | 660 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845500) |
| September 28, 2026 | NCT07844512 | Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing... | The First Hospital of Jilin University | Phase 3 | Recruiting | Pain Management, Overweight , Obesity, Respiration; Sleep Disorder | 148 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844512) |
| September 28, 2026 | NCT07843498 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight | 3,900 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843498) |
| September 28, 2026 | NCT07843485 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Type 2 Diabetes | 600 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843485) |
| September 28, 2026 | NCT07843472 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established... | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Cardiovascular Disease | 2,500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843472) |
| September 25, 2026 | NCT07843082 | Exercise and Tissue-Specific Insulin Sensitivity in South Asian and Nordic Women With Previous Gestational Diabetes | Oslo University Hospital | Not applicable | Completed | Diabetes, Obesity & Overweight | 43 | Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843082) |
| September 25, 2026 | NCT07840846 | Standardized Large Yellow Tea Extract for Glucose and Lipid Metabolism in Overweight Adults With Hypertriglyceridemia | The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) | Not applicable | Not yet recruiting | Hypertriglyceridemia, Overweight , Obesity | 138 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840846) |
| September 25, 2026 | NCT07840807 | Traditional Chinese Medicine Fasting Therapy, Ketone Levels, and Metabolic Improvements | The Seventh Affiliated Hospital of Sun Yat-sen University | Observational | Completed | Obesity & Overweight, Diabete Type 2, Metabolic Syndrome | 1,149 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840807) |
| September 25, 2026 | NCT07840274 | Effects of Daily Kefir Consumption During Medical Nutrition Therapy on Body Composition and Psychological Well-Being in Women With Obesity | Pınar Göbel | Not applicable | Completed | Obesity & Overweight, Gut Microbiota, Body Composition | 68 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840274) |
| September 24, 2026 | NCT07840170 | Whole Food Fibers for Support of Key Gut Bacteria for Human Health | Purdue University | Not applicable | Not yet recruiting | Prediabetes or Overweight | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840170) |
| September 24, 2026 | NCT07837973 | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Alveus Therapeutics, Inc. | Phase 2 | Recruiting | Overweight , Obesity, Adults | 220 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837973) |
| September 23, 2026 | NCT07836582 | Physical Activity for Depressive Symptoms in Adults With Obesity: A Randomized Controlled Feasibility Trial | Universite du Quebec en Outaouais | Not applicable | Not yet recruiting | Obesity & Overweight, Depression Disorders | 26 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836582) |
| September 23, 2026 | NCT07836322 | SHIFT-TB: Nutrition Intervention and Evaluation | National University of Singapore | Not applicable | Recruiting | Underweight, Overweight and Obesity | 700 | Cambodia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836322) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Eli Lilly and Company | 49 | November 4, 2026 |
| Novo Nordisk A/S | 48 | October 19, 2026 |
| Amgen | 23 | November 6, 2026 |
| Pfizer | 23 | November 5, 2026 |
| Hoffmann-La Roche | 13 | November 5, 2026 |
| Shanghai Minwei Biotechnology Co., Ltd | 13 | September 4, 2026 |
| AstraZeneca | 10 | November 6, 2026 |
| BrightGene Bio-Medical Technology Co., Ltd. | 8 | November 5, 2026 |
| Beijing QL Biopharmaceutical Co.,Ltd | 8 | November 4, 2026 |
| Kailera | 7 | November 9, 2026 |
| University of Alabama at Birmingham | 7 | September 18, 2026 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | 7 | September 8, 2026 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 6 | November 6, 2026 |
| Vincentage Pharma Co., Ltd | 6 | January 16, 2026 |
| Gan & Lee Pharmaceuticals. | 6 | December 18, 2025 |
| University Hospital, Gentofte, Copenhagen | 5 | October 27, 2026 |
| Regeneron Pharmaceuticals | 5 | October 26, 2026 |
| Innovent Biologics (Suzhou) Co. Ltd. | 5 | September 9, 2026 |
| Pamukkale University | 5 | August 4, 2026 |
| Johns Hopkins University | 5 | June 23, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 529 | November 9, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 166 | November 5, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 155 | November 9, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 99 | November 6, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 92 | November 5, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 40 | November 6, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 10 | October 27, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 10 | September 22, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 4 | October 23, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 348 | November 9, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 187 | November 9, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 79 | November 2, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 65 | October 28, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 61 | November 5, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 60 | November 9, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 53 | November 2, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 48 | October 28, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 47 | November 3, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 42 | November 5, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 34 | October 28, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 32 | October 28, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 32 | October 28, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 31 | October 28, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 31 | October 19, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 30 | October 28, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 29 | October 28, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 29 | October 28, 2026 |
| [Puerto Rico](https://specstream.ai/data/clinical-trials/country/puerto-rico) | 28 | October 28, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 25 | October 28, 2026 |
| [India](https://specstream.ai/data/clinical-trials/country/india) | 22 | November 6, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 22 | August 18, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 20 | November 6, 2026 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 19 | November 4, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 19 | October 13, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).